Alvogen Appoints CFO
This article was originally published in Scrip
Kevin Bain, who was recently Alvogen's chief financial officer (CFO), has been appointed CFO of its biotech sister company, Alvotech. He will continue as executive vice-president of strategic development at Alvogen where Graham Baker has been appointed the new CFO - effective Nov.1, 2015. Prior to Alvogen, Baker spent 20 years' at AstraZeneca where he was most recently vice-president of finance for the company's international business.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.